机器人辅助切除III期肺癌:一项国际回顾性研究
这项国际多中心回顾性研究纳入2007-2016年在7个高容量中心接受机器人辅助切除的210例NSCLC和13例类癌(临床明显或隐匿N2)患者,评估围手术期结局、复发和总生存。结果显示中转开胸率9.9%、严重并发症10.3%,NSCLC患者3年总生存61.2%,淋巴结阳性数≤2者生存显著优于>2者。
要点
- 机器人辅助肺叶切除在IIIA期NSCLC或类癌中安全有效,中转率和并发症低。
- NSCLC患者3年总生存61.2%,≤2枚阳性淋巴结者生存显著优于>2枚者(P=0.012)。
- 接受新辅助化疗的34例均获R0切除,5例(15%)中转,4例(12%)发生III-IV级并发症。
核心结论
- 机器人辅助肺叶切除在III期NSCLC或类癌患者中安全有效,中转率和并发症低。
- 在NSCLC患者中,包括接受诱导化疗者,生存与开胸手术报道相似。
研究设计与样本
- 回顾性多中心研究,纳入2007-2016年在7个高容量中心连续接受机器人辅助切除的临床明显或隐匿N2患者,共210例NSCLC和13例类癌。
主要发现
- N2病变术前诊断72例(32%),术中诊断151例(68%)。
- 有数据者中98.4%手术切缘阴性。
- 34例(15.2%)接受新辅助治疗,140例(63%)接受术后治疗,49例(22%)仅手术。
- 22例(9.9%)中转开胸,23例(10.3%)发生严重(III-IV级)术后并发症,平均住院5.3天。
- 中位随访18个月(四分位距8-33),NSCLC患者3年总生存61.2%;亚组中接受诱导治疗者3年总生存60.3%(P=0.6)。
关键数值与推荐
- NSCLC患者中阳性淋巴结≤2枚者总生存显著优于>2枚者(P=0.012)。
- 19例(8.5%)发生局部复发。
- 接受新辅助化疗的34例均R0切除,5例(15%)需中转(无一因出血中转),4例(12%)发生III或IV级术后并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Minimally invasive surgery is accepted for early-stage lung cancer, but its role in locally advanced disease is controversial, especially using a robotic platform. The aim of this retrospective study was to assess the safety and effectiveness of robot-assisted resection in patients with Stage IIIA non-small-cell lung cancer (NSCLC) or carcinoid tumours in the series as a whole and in different subgroups according to adjuvant treatment. METHODS: This was a retrospective multicentre study of consecutive patients with clinically evident or occult N2 disease (210 NSCLC and 13 carcinoid) who, in 2007-2016, underwent robot-assisted resection at 7 high-volume centres. Perioperative outcomes, recurrences and overall survival were assessed. RESULTS: N2 disease was diagnosed preoperatively in 72 (32%) patients and intraoperatively in 151 (68%) patients. Surgical margins were negative in 98.4% of cases with available data. Thirty-four (15.2%) patients received neoadjuvant treatment, 140 (63%) patients received postoperative treatment, and 49 (22%) patients underwent surgery only. There were 22 (9.9%) conversions to thoracotomy, 23 (10.3%) had serious (Grades III-IV) postoperative morbidity and the mean hospital stay was 5.3 days. Complications and outcomes did not differ significantly between treatment groups. Of the 34 patients who were given neoadjuvant chemotherapy, all had R0 resection, 5 (15%) patients required conversion but none required conversion because of bleeding and 4 (12%) patients had Grade III or IV postoperative complications. After a median of 18 (interquartile range 8-33) months, 3-year overall survival in NSCLC patients was 61.2% and 60.3% (P = 0.6) of patients in the subgroup were given induction treatment. However, overall survival was significantly better (P = 0.012) in NSCLC patients with ≤2 positive nodes (vs >2). Nineteen (8.5%) patients developed local recurrence. CONCLUSIONS: Robot-assisted lobectomy is safe and effective in patients with Stage III NSCLC or carcinoid tumours with low conversions and complications. Among patients with NSCLC, including those who were given induction chemotherapy, survival was similar to that reported for open surgery.
引用
- Veronesi G, Park B, Cerfolio R, et al. Robotic resection of Stage III lung cancer: an international retrospective study. Eur J Cardiothorac Surg. 2018. PMID: 29718155. doi:10.1093/ejcts/ezy166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。